Екатерина Щербакова (ночной линейный редактор)
Thing two is that SEC enforcement has seriously declined under the Trump administration and probably is going to continue to decline. The SEC just has been declining in power generally over the last, I would say 20, 30 years. So we don’t really have an enforcement mechanism. One of the things that has been known for a while is you’ll see in pharmaceutical stocks around certain big conferences, the shares trade before the abstracts of studies are released. So somebody knows what’s in those abstracts and they’re trading on that information before it becomes public. This is a really well-known phenomenon and no one has done anything about it. So those are two things that are involved.
，推荐阅读快连下载安装获取更多信息
Андрей Шеньшаков，更多细节参见电影
15+ Premium newsletters by leading experts。业内人士推荐体育直播作为进阶阅读